SLC5A2 and type 2 diabetes mellitus: In the last seven years, clinical trials have demonstrated that many SGLT-2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA), which were both initially approved as glucose-lowering medications, can reduce the risk of cardiovascular events in patients with T2D and established atherosclerotic CVD (3, 4).